Cybin Inc (HELP) Stock Forecast & Price Target

Helus Pharma is a clinical-stage biotechnology company that has a differentiated approach in developing neuropsychiatry drugs. Its lead asset, HLP003, is a unique oral deuterated psilocin analog in Phase 3 clinical trials, which has demonstrated a significant improvement in patients with major depressive disorder, de-risking the ongoing Phase 3 program. The company is well-positioned to support operations with a strong balance sheet and experienced leadership, while its other asset, HLP004, offers additional upside potential in a large and underserved market for generalized anxiety disorder. With a solid pipeline, strong financials and a supportive environment for psychedelic therapies, Helus is poised for success in the growing neuropsychiatric space.

Helus Pharma is experiencing a negative outlook due to the fact that their current Phase 3 program for HLP003, while aligned with FDA industry guidance, is adjunctive and the efficacy of the NSA as an added treatment to background antidepressants remains unknown. Additionally, data on their HLP004 program, aimed at treating generalized anxiety disorder, is lacking and a second shot on goal. The estimated peak annual revenues for HLP003 are $3.9 billion, but with estimated risks, the current value of HLP003 is $52 per share, significantly lower than its previous value of $72 per share.